急性脑梗死患者C反应蛋白、ApoA1、Fib检测的临床意义

Clinical significance of C-Reaction protein,ApoA1 and Fib in patients with cerebral infarction

目的探讨急性脑梗死(ACI)患者血清C反应蛋白(CRP)、载脂蛋白A(ApoA1)、纤维蛋白原(Fib)检测的临床意义。方法测定136例ACI患者、67例正常对照组血清CRP、ApoA1、Fib的水平,观察比较不同类型ACI患者的血清CRP、ApoA1、Fib含量差异,对发病后48h后病情发展变化进行评定,将(ACI)患者分为进展型与完全型脑梗死两组。根据NIHSS评分将临床神经功能损害程度分为:轻型、中型、重型。结果CRP水平:进展组高于完全组和对照组(P<0.05),NIHSS重型组明显高于中型、轻型组(P<0.05);ApoA1水平:进展组明显低于完全组和对照组,重型组明显低于中型、轻型组(P<0.05)。Fib水平:进展组和完全组均明显高于对照组,NIHSS重型组明显高于中型?轻型组(P<0.05)CRP与ApoA1,Fib均有相关性,相关系数分别是(r=-0.557,r=0.643)P<0.05。结论CRP、ApoA1、Fib一定程度上是预测ACI患者病情及发展方向的生化指标。

Objective To observe the clinical evaluation of C-reactive protein（CRP） ,ApoA1 and Fib content in patients with acute cerebral infarction （ACI）. Methods The content of serum CRP, ApoA1 and Fib in 136 patients with ACI and 67 normal control were measured. The changes of CRP, ApoA1 and Fib were compared with patients of different pathogenetic condition. The patients were divided into progressive stroke and complete stroke through the disease progress evaluation 48h after cerebral ischemic stroke. The severity of neurological impairment was assessed by National Institutesof Health Stroke Scale（NIHSS）. The patients were divided into light group, middle group and severe group. Results CRP level：the progressive group were significantly higher than that in the complete group and control group （P 〈 0.05 ）, and the severe group were higher than that in light and middle groups（ P 〈 0. 05 ）. ApoA1 level：the progressive group was significantly lower than that in the complete group and control group（ P 〈 0.05 ）, and the severe group was lower than that in light and middle groups（P 〈 0. 05 ）. Fib level：the progressive group and complete group were significantly higher than control group（P 〈0.05） ,and the severe group was higher than that in light and middle groups（P 〈0.05）. The changes of CRP level correlated with ApoA1 level（ r = 0. 643, P 〈 0.05 ） positively and Fib （ r = - 0.557, P 〈 0. 05 ） negatively. Conclusion The CRP,ApoA1 and Fib can be the important biological markers to judge the severity and progress direction of ACI.